Genetic Testing in Prostate Cancer

Overview

Journal Curr Oncol Rep

Publisher Current Science

Specialty Oncology

Date 2020 Jan 25

PMID 31974718

Citations 18

Authors

Alexandra O Sokolova

Heather H Cheng

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: This review summarizes recent advances in prostate cancer (PCa) genetics.

Recent Findings: Upwards of 20% of metastatic castration-resistant prostate tumors (mCRPC) carry homologous recombination (HR) repair gene mutations, of which ~ 10% are germline (inherited). Another ~ 5% exhibit microsatellite instability (MSI-H) and/or mismatch repair deficiency (MMRd). Pembrolizumab is approved for tumors with MMRd, thus patients with mCRPC and MMRd are candidates for pembrolizumab. Emerging data indicate that platinum chemotherapy and poly ADP-ribose polymerase inhibitors (PARPi) are effective in PCa exhibiting HR deficiency. NCCN guidelines now recommend germline and somatic tumor testing in specific clinical scenarios due to treatment and family implications. Genetic testing in PCa patients may inform prognosis, treatment options, and have implications for family counseling. PARPi, platinum chemotherapy, and immune checkpoint inhibitors are promising targeted therapies for PCa with specific molecular features. Therapeutic advances, along with importance to relatives, are driving genetic testing in prostate cancer.

Citing Articles

A Cross-sectional Survey of Physicians to Understand Biomarker Testing and Treatment Patterns in Patients with Prostate Cancer in the USA, EU5, Japan, and China.

Gratzke C, Aggarwal H, Kim J, Chaignaud H, Oskar S Eur Urol Open Sci. 2025; 71():148-155.

PMID: 39845739 PMC: 11751505. DOI: 10.1016/j.euros.2024.07.113.

Innovative Drug Modalities for the Treatment of Advanced Prostate Cancer.

Capuozzo M, Santorsola M, Ianniello M, Ferrara F, Zovi A, Petrillo N Diseases. 2024; 12(5).

PMID: 38785742 PMC: 11119780. DOI: 10.3390/diseases12050087.

Toward Informed Selection and Interpretation of Clinical Genomic Tests in Prostate Cancer.

Vandekerkhove G, Giri V, Halabi S, McNair C, Hamade K, Bitting R JCO Precis Oncol. 2024; 8:e2300654.

PMID: 38547422 PMC: 10994438. DOI: 10.1200/PO.23.00654.

Genetic Signatures for Distinguishing Chemo-Sensitive from Chemo-Resistant Responders in Prostate Cancer Patients.

Gumenku L, Sekhoacha M, Abrahams B, Mashele S, Shoko A, Erukainure O Curr Issues Mol Biol. 2024; 46(3):2263-2277.

PMID: 38534761 PMC: 10969469. DOI: 10.3390/cimb46030145.

Prostate cancer patient stratification by molecular signatures in the Veterans Precision Oncology Data Commons.

Hernandez K, Venkat A, Elbers D, Bihn J, Brophy M, Do N Cold Spring Harb Mol Case Stud. 2023; 9(4).

PMID: 38050021 PMC: 10815278. DOI: 10.1101/mcs.a006298.

References

Gudmundsson J, Sulem P, Gudbjartsson D, Blondal T, Gylfason A, Agnarsson B . Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility. Nat Genet. 2009; 41(10):1122-6. PMC: 3562712. DOI: 10.1038/ng.448. View

Castro E, Romero-Laorden N, Del Pozo A, Lozano R, Medina A, Puente J . PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2019; 37(6):490-503. DOI: 10.1200/JCO.18.00358. View

Eeles R, Olama A, Benlloch S, Saunders E, Leongamornlert D, Tymrakiewicz M . Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet. 2013; 45(4):385-91, 391e1-2. PMC: 3832790. DOI: 10.1038/ng.2560. View

Gallagher D, Gaudet M, Pal P, Kirchhoff T, Balistreri L, Vora K . Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. Clin Cancer Res. 2010; 16(7):2115-21. PMC: 3713614. DOI: 10.1158/1078-0432.CCR-09-2871. View

Page E, Bancroft E, Brook M, Assel M, Hassan Al Battat M, Thomas S . Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. Eur Urol. 2019; 76(6):831-842. PMC: 6880781. DOI: 10.1016/j.eururo.2019.08.019. View

Marshall C, Fu W, Wang H, Baras A, Lotan T, Antonarakis E . Prevalence of DNA repair gene mutations in localized prostate cancer according to clinical and pathologic features: association of Gleason score and tumor stage. Prostate Cancer Prostatic Dis. 2018; 22(1):59-65. PMC: 6372344. DOI: 10.1038/s41391-018-0086-1. View

Cheng H, Sokolova A, Schaeffer E, Small E, Higano C . Germline and Somatic Mutations in Prostate Cancer for the Clinician. J Natl Compr Canc Netw. 2019; 17(5):515-521. DOI: 10.6004/jnccn.2019.7307. View

Cheng H, Pritchard C, Boyd T, Nelson P, Montgomery B . Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2016; 69(6):992-5. PMC: 4909531. DOI: 10.1016/j.eururo.2015.11.022. View

Pomerantz M, Spisak S, Jia L, Cronin A, Csabai I, Ledet E . The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer. Cancer. 2017; 123(18):3532-3539. PMC: 5802871. DOI: 10.1002/cncr.30808. View

10.

Velho P, Silberstein J, Markowski M, Luo J, Lotan T, Isaacs W . Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer. Prostate. 2018; 78(5):401-407. PMC: 6524639. DOI: 10.1002/pros.23484. View

11.

Gudmundsson J, Sulem P, Gudbjartsson D, Masson G, Agnarsson B, Benediktsdottir K . A study based on whole-genome sequencing yields a rare variant at 8q24 associated with prostate cancer. Nat Genet. 2012; 44(12):1326-9. PMC: 3562711. DOI: 10.1038/ng.2437. View

12.

Robinson D, Van Allen E, Wu Y, Schultz N, Lonigro R, Mosquera J . Integrative clinical genomics of advanced prostate cancer. Cell. 2015; 161(5):1215-1228. PMC: 4484602. DOI: 10.1016/j.cell.2015.05.001. View

13.

Abida W, Cheng M, Armenia J, Middha S, Autio K, Vargas H . Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade. JAMA Oncol. 2018; 5(4):471-478. PMC: 6459218. DOI: 10.1001/jamaoncol.2018.5801. View

14.

Castro E, Goh C, Olmos D, Saunders E, Leongamornlert D, Tymrakiewicz M . Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol. 2013; 31(14):1748-57. PMC: 3641696. DOI: 10.1200/JCO.2012.43.1882. View

15.

Alsop K, Fereday S, Meldrum C, DeFazio A, Emmanuel C, George J . BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol. 2012; 30(21):2654-63. PMC: 3413277. DOI: 10.1200/JCO.2011.39.8545. View

16.

Na R, Zheng S, Han M, Yu H, Jiang D, Shah S . Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death. Eur Urol. 2016; 71(5):740-747. PMC: 5535082. DOI: 10.1016/j.eururo.2016.11.033. View

17.

Ewing C, Ray A, Lange E, Zuhlke K, Robbins C, Tembe W . Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med. 2012; 366(2):141-9. PMC: 3779870. DOI: 10.1056/NEJMoa1110000. View

18.

Nicolosi P, Ledet E, Yang S, Michalski S, Freschi B, OLeary E . Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines. JAMA Oncol. 2019; 5(4):523-528. PMC: 6459112. DOI: 10.1001/jamaoncol.2018.6760. View

19.

Olama A, Kote-Jarai Z, Schumacher F, Wiklund F, Berndt S, Benlloch S . A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. Hum Mol Genet. 2012; 22(2):408-15. PMC: 3526158. DOI: 10.1093/hmg/dds425. View

20.

Bottcher R, Kweldam C, Livingstone J, Lalonde E, Yamaguchi T, Huang V . Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations. BMC Cancer. 2018; 18(1):8. PMC: 5751811. DOI: 10.1186/s12885-017-3976-z. View